Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Production of Formed Elements01:34

Production of Formed Elements

1.3K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
1.3K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

3.8K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
3.8K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transferrin in combination with induction chemotherapy improves outcomes in mouse models of acute myeloid leukemia.

Science translational medicine·2026
Same author

Microglial clonal dynamics and the impact of clonal hematopoiesis in autologously transplanted rhesus macaques.

Cell reports·2026
Same author

Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.

Blood advances·2026
Same author

Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML.

Blood·2026
Same author

Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.

Cell reports. Medicine·2026
Same author

The prevalence and clinical significance of clonal monocytosis.

Blood·2026
Same journal

ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression.

The Journal of clinical investigation·2026
Same journal

A peripheral subpopulation of retinal pigment epithelium resists oxidative damage through SERPINE3-mediated Caspase-1 inhibition.

The Journal of clinical investigation·2026
Same journal

PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.

The Journal of clinical investigation·2026
Same journal

CD20+ T follicular helper-like cells drive antigen-specific autoimmunity in bullous pemphigoid.

The Journal of clinical investigation·2026
Same journal

Fate-mapping infiltrating monocytes following experimental myocardial infarction revealsdifferentiation trajectories in the infarcted heart.

The Journal of clinical investigation·2026
Same journal

Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adults.

The Journal of clinical investigation·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.4K

Clonal hematopoiesis and hematological malignancy.

William G Dunn1,2, Matthew A McLoughlin1, George S Vassiliou1,2

  • 1Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.

The Journal of Clinical Investigation
|October 1, 2024
PubMed
Summary
This summary is machine-generated.

Clonal hematopoiesis (CH), driven by mutations, is common in older adults. Understanding CH mutations helps predict and prevent progression to myeloid cancers.

More Related Videos

Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K

Related Experiment Videos

Last Updated: Jun 11, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.4K
Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K

Area of Science:

  • Hematology
  • Genetics
  • Oncology

Background:

  • Clonal hematopoiesis (CH) involves the expansion of mutated hematopoietic stem cells, increasing with age.
  • CH is often subclinical but can progress to myeloid neoplasms like leukemia.
  • Recent advances enhance understanding of CH molecular landscape and associated risks.

Purpose of the Study:

  • To provide an overview of CH driver mutations.
  • To discuss the pathophysiology of CH.
  • To inform myeloid malignancy risk estimation in CH carriers.

Main Methods:

  • Review of current literature on clonal hematopoiesis.
  • Analysis of the spectrum of CH driver mutations.
  • Examination of the link between CH pathophysiology and myeloid neoplasia risk.

Main Results:

  • CH is prevalent in individuals over 70.
  • Specific driver gene mutations in CH confer varying risks of myeloid neoplasia.
  • Improved risk stratification for CH carriers is now possible.

Conclusions:

  • Advances in understanding CH enable precise myeloid neoplasia risk assessment.
  • This knowledge facilitates the development of strategies to intercept CH progression.
  • Targeted interventions aim to prevent CH from evolving into hematologic malignancies.